The forecast for cardiac glycosides sales in Canada from 2024 to 2028 shows a stable market, with values at $0.3 in 2024 and 2025, declining to $0.2 from 2026 to 2028 US Dollars PPP per Capita. Compared to the values in 2023, the market was at the same level as 2024 (since actual past data wasn't provided here), presenting zero growth for the first two years and a negative trend of approximately 33% from 2025 to 2026. The Compound Annual Growth Rate (CAGR) over the five-year period suggests a gentle decline per year.
Future trends to watch:
-Monitoring changes in healthcare regulations may impact the demand for cardiac treatments.
-Innovations in alternative therapies could influence market dynamics.
-Consider the effects of demographic shifts, given Canada's aging population.
